Propanc Biopharma Inc

Propanc Biopharma, Inc. is an Australian biopharmaceutical company focused on developing cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancers. The firm's lead product, PRP, is a formulation in the preclinical phase designed to amplify the anti-cancer effects of multiple enzymes. Propanc engages in research collaborations, including a joint drug discovery program called POP1 with the University of Jaén, and a separate joint initiative with the Universities of Jaén and Granada to investigate changes in genetic and protein expression observed in cancer cells. Founded in 2007 and headquartered in Camberwell, Australia, the company was formerly known as Propanc Health Group Corporation before rebranding to Propanc Biopharma, Inc. in April 2017.